CEO Sean Bohen was paid $3,178,990 in fiscal year 2025, ↓ down 60.9% from fiscal year 2024, the 25th percentile of its disclosed peer group (SEC filing 0001193125-26-191956 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$3,178,990 ↓ Sean Bohen total, FY2025 | 25th CEO pay percentile vs peers | — CEO-to-median pay ratio | 99.05% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
OLMA's next annual pay disclosure, estimated April 30, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Sean Bohen | $699,920 | $0 | $0 | $2,002,000 | $461,900 | $0 | $15,170 | $3,178,990 |
| President and Chief Executive Officer | ||||||||
| Shawnte Mitchell | 391,875 | 50,000 | 0 | 1,386,000 | 207,900 | 0 | 14,975 | 2,050,750 |
| Chief Legal Officer and Corporate Secretary | ||||||||
| Shane Kovacs | 562,640 | 0 | 0 | 985,600 | 324,925 | 0 | 15,170 | 1,888,335 |
| Chief Operating and Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Sean Bohen | $3,178,990 | $8,130,556 | — | ↓ −4,951,566 |
| Shawnte Mitchell | 2,050,750 | — | — | — |
| Shane Kovacs | 1,888,335 | 4,280,130 | — | ↓ −2,391,795 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Olema Pharmaceuticals's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper OLMA reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses OLMA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named OLMA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Andrew Rappaport | Independent Director | $121,438 |
| Cynthia Butitta | Independent Director | $126,841 |
| Cyrus L. Harmon, Ph.D | Independent Director | $109,438 |
| Gorjan Hrustanovic, Ph.D | Independent Director | $116,188 |
| Graham Walmsley, M.D., Ph.D | Independent Director | $114,688 |
| Ian Clark | Independent Director | $145,688 |
| Sandra Horning, M.D | Independent Director | $118,188 |
| Scott Garland | Independent Director | $119,387 |
| Yi Larson | Independent Director | $125,906 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| G. Walmsley Graham | Director | 2026-06-18 | A | 29,500 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Rappaport | Director | 2026-06-18 | A | 29,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Prakash Raman | Director | 2026-06-18 | A | 29,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra Horning | Director | 2026-06-18 | A | 29,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Yi Larson | Director | 2026-06-18 | A | 29,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ian Clark | Director | 2026-06-18 | A | 29,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gorjan Hrustanovic | Director | 2026-06-18 | A | 29,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Garland | Director | 2026-06-18 | A | 29,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cynthia Butitta | Director | 2026-06-18 | A | 29,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cyrus Harmon | Director | 2026-06-18 | A | 29,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| BVF PARTNERS L P/IL | Director | 2026-06-18 | A | 29,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cyrus Harmon | Director | 2026-07-23 | D | 12,500 | 12 | 144,738 | Common, open-market sale | Form 4 ↗ |
| Cyrus Harmon | Director | 2026-07-24 | D | 12,500 | 12 | 146,425 | Common, open-market sale | Form 4 ↗ |
| Jason O'Byrne | CHIEF FINANCIAL OFFICER | 2026-09-01 | A | 650,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Shane Kovacs | Option | — | — | — | — | — | $985,600 |
| Sean Bohen | Option | — | — | — | — | — | 2,002,000 |
| Shawnte Mitchell | Option | — | — | — | — | — | 1,386,000 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Shane Kovacs | $0 | $0 | $985,600 | 0.0% |
| Sean Bohen | 0 | 0 | 2,002,000 | 0.0% |
| Shawnte Mitchell | 0 | 0 | 1,386,000 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Shawnte Mitchell | Option | 450,000 | 4.37 | — |
| Sean Bohen | Option | 336,646 | 15.25 | — |
| Shane Kovacs | Option | 164,938 | 15.25 | — |
| Sean Bohen | Option | 650,000 | 4.37 | — |
| Sean Bohen | Option | 160,417 | 4.87 | — |
| Shane Kovacs | Option | 320,000 | 4.37 | — |
| Sean Bohen | Option | 33,845 | 7.02 | — |
| Shane Kovacs | Option | 58,334 | 4.87 | — |
| Shane Kovacs | Option | 10,292 | 7.02 | — |
Our executive compensation program reflects our philosophy of aligning executive compensation with company and individual performance and value creation for the company. We also consider current market practices and trends, and supporting our goals to deliver on our mission and objectives. Executive compensation consists of a base salary and bonus, adjusted based on market trends, and an equity component, including annual refresh grants, which are subject to time-based vesting to incentivize long-term value creation for stockholders.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-17 | 67,969,902 | 653,979 | 15,867 | 99.05% | Passed |
| 2025 | 2025-06-10 | 54,057,177 | 2,297,482 | 54,317 | 95.92% | Passed |
| 2024 | 2024-06-13 | 45,174,223 | 787,068 | 8,069 | 98.29% | Passed |
| 2023 | 2023-06-15 | 18,713,603 | 1,912,571 | 5,021,093 | 90.73% | Passed |
| 2022 | 2022-06-16 | 21,851,764 | 3,812,824 | 1,922,018 | 85.14% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-17 | 99.05%a |
| 2025 | 2025-06-10 | 95.92%b |
| 2024 | 2024-06-13 | 98.29%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Ian ClarkIndependent · Compensation | $80,000 | — | $65,688 | — | — | $145,688 |
| Cynthia ButittaIndependent · Audit | 61,153 | — | 65,688 | — | — | 126,841 |
| Yi LarsonIndependent · Audit | 60,218 | — | 65,688 | — | — | 125,906 |
| Andrew RappaportIndependent · Compensation | 55,750 | — | 65,688 | — | — | 121,438 |
| Scott GarlandIndependent · Nominating and Corporate Governance | 53,699 | — | 65,688 | — | — | 119,387 |
| Sandra Horning, M.DIndependent · Science and Technology | 52,500 | — | 65,688 | — | — | 118,188 |
| Gorjan Hrustanovic, Ph.DIndependent · Audit | 50,500 | — | 65,688 | — | — | 116,188 |
| Graham Walmsley, M.D., Ph.DIndependent · Science and Technology | 49,000 | — | 65,688 | — | — | 114,688 |
| Cyrus L. Harmon, Ph.DIndependent · Audit | 43,750 | — | 65,688 | — | — | 109,438 |
| Sean Bohen, M.D., Ph.DEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Raman (Dr.)Independent | — | — | — | — | — | — |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 7,500 / 7,500 / 7,500 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $506,570 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $506,570 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Olema Pharmaceuticals names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Olema Pharmaceuticals.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Cogent Biosciences | 2025 | Andrew Robbins | $724,554 | $12,993,250 | $13,447,680 | $561,600 | $27,762,684 |
| 2 | Arcus Biosciences | 2025 | Terry Rosen | 775,000 | 2,199,450 | 6,008,860 | 658,750 | 9,656,813 |
| 3 | Praxis Precision Medicines | 2025 | Marcio Souza | 659,200 | 2,368,125 | 3,691,125 | 1,483,200 | 8,708,648 |
| 4 | MeiraGTx | 2025 | Alexandria Forbes | 840,000 | 5,823,500 | — | — | 8,330,006 |
| 5 | Terns Pharmaceuticals | 2024 | Amy Burroughs | 563,701 | 807,750 | 6,476,968 | 375,000 | 8,240,502 |
| 6 | Vir Biotechnology | 2025 | Marianne De Backer | 950,000 | 2,296,800 | 3,507,360 | 1,002,750 | 7,834,045 |
| 7 | Syndax Pharmaceuticals | 2025 | Michael Metzger | 754,300 | 2,021,965 | 3,454,360 | 848,588 | 7,089,213 |
| 8 | Arvinas | 2025 | John Houston | 706,236 | 2,685,840 | 2,671,051 | 457,000 | 6,534,127 |
| 9 | AnaptysBio | 2025 | Daniel Faga | 706,011 | 1,592,001 | 3,345,653 | 465,968 | 6,133,943 |
| 10 | Alumis | 2025 | Martin Babler | 680,830 | 0 | 4,743,220 | 524,239 | 5,948,289 |
| 11 | ORIC Pharmaceuticals | 2025 | Jacob Chacko | 657,500 | 826,000 | 3,634,560 | 434,000 | 5,567,164 |
| 12 | Xencor | 2025 | Bassil Dahiyat | 742,800 | 1,552,892 | 2,727,018 | 490,248 | 5,521,205 |
| 13 | Cullinan Therapeutics | 2025 | Nadim Ahmed | 698,476 | 1,697,400 | 2,234,340 | 419,086 | 5,100,006 |
| 14 | KalVista Pharmaceuticals | 2025 | Benjamin Palleiko | 477,202 | 3,731,160 | 0 | 0 | 5,094,999 |
| 15 | Kura Oncology | 2025 | Troy Wilson | 700,000 | 0 | 3,297,250 | 630,000 | 4,735,016 |
| 16 | Zenas BioPharma | 2025 | Leon Moulder | 520,000 | 0 | 3,769,200 | 371,800 | 4,661,000 |
| 17 | Relay Therapeutics | 2025 | Sanjiv Patel | 707,846 | 0 | 3,513,900 | 424,708 | 4,646,454 |
| 18 | Erasca | 2025 | Jonathan Lim | 670,400 | 0 | 3,135,250 | 482,688 | 4,298,838 |
| 19 | Aura Biosciences | 2025 | Elisabet de los Pinos | 645,483 | 1,492,378 | 1,513,293 | 284,013 | 3,956,167 |
| 20 | Nuvation Bio | 2025 | David Hung | 650,016 | 0 | 2,674,636 | 536,250 | 3,876,736 |
| 21 | Annexon | 2025 | Douglas Love | 670,833 | 0 | 2,522,260 | 371,250 | 3,579,202 |
| 22 | Olema Pharmaceuticals | 2025 | Sean Bohen | 699,920 | 0 | 2,002,000 | 461,900 | 3,178,990 |
| 23 | Inhibrx Biosciences | 2025 | Mark Lappe | 695,250 | 0 | 0 | 479,723 | 2,892,473 |
| 24 | Amylyx Pharmaceuticals (amlx) | 2025 | Justin Klee | 686,200 | 650,226 | 817,783 | 548,098 | 2,719,807 |
| 25 | Keros Therapeutics | 2025 | Jasbir Seehra | 700,000 | 1,426,280 | 0 | 398,125 | 2,540,204 |
| 26 | Kodiak Sciences | 2025 | Victor Perlroth | 792,497 | 0 | 923,032 | 772,824 | 2,499,221 |
| 27 | Verastem | 2025 | Daniel Paterson | 674,000 | 1,161,661 | 0 | 489,324 | 2,349,975 |
| 28 | Alector | 2025 | Arnon Rosenthal | 678,100 | 422,876 | 558,216 | 325,488 | 1,995,018 |
| 29 | Arcturus Therapeutics | 2025 | Joseph Payne | 750,000 | 0 | 941,000 | 0 | 1,691,000 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Olema Pharmaceuticals | 110% | Options 100 | not disclosed | Aon |
| Alector | 80% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Alumis | not disclosed | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Amylyx Pharmaceuticals (amlx) | 106.5% | not disclosed | No | Pearl Meyer |
| AnaptysBio | 110% | not disclosed | No | Alpine Rewards |
| Annexon | 100% of target% | not disclosed | not disclosed | Alpine Rewards |
| Arcturus Therapeutics | not disclosed | Options 100 | not disclosed | not disclosed |
| Arcus Biosciences | 100% | Options 67 · RSU 33 | not disclosed | Radford |
| Arvinas | 108% | Options 50 · RSU 50 | not disclosed | Aon (Aon's Human Capital Solutions practice, a division of Aon plc) |
| Aura Biosciences | not disclosed | not disclosed | not disclosed | Pay Governance |
| Cogent Biosciences | 135% | not disclosed | No | Compensia |
| Cullinan Therapeutics | not disclosed | not disclosed | not disclosed | Compensia (through June 2025); Pay Governance (since June 2025) |
| Erasca | 120% | Options 100 | not disclosed | Alpine Rewards, LLC |
| Inhibrx Biosciences | not disclosed | Option 100 | not disclosed | not disclosed |
| KalVista Pharmaceuticals | not disclosed | not disclosed | No | Aon |
| Keros Therapeutics | 87.5% | RSU 50 · PSU 50 | No | Aon (Human Capital Solutions practice) |
| Kodiak Sciences | 150% | Options 100 | not disclosed | Compensia, Inc. |
| Kura Oncology | 150% | not disclosed | No | Alpine Rewards |
| MeiraGTx | not disclosed | RSU 100 | not disclosed | Total Compensation Solutions |
| Nuvation Bio | not disclosed | not disclosed | not disclosed | FW Cook |
| ORIC Pharmaceuticals | not disclosed | not disclosed | not disclosed | Aon |
| Praxis Precision Medicines | not disclosed | Option 50 · RSU 50 | not disclosed | Frederic W. Cook & Co., Inc. |
| Relay Therapeutics | 100% | Option 100 | not disclosed | Aon's Human Capital Solutions practice, a division of Aon plc |
| Syndax Pharmaceuticals | 150% | Options 34 · PSU 33 · RSU 33 | Yes — Company's three-year total shareholder return (TSR) as measured against the Nasdaq Biotechnology Index components TSRs | Aon |
| Terns Pharmaceuticals | 120% | not disclosed | No | Alpine Rewards |
| Verastem | not disclosed | not disclosed | not disclosed | Pearl Meyer |
| Vir Biotechnology | 125% | Options 67 · RSU 33 | not disclosed | Semler Brossy |
| Xencor | 110% | Options 60 · RSU 40 | not disclosed | Aon |
| Zenas BioPharma | not disclosed | Option 100 | not disclosed | Alpine |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Sean Bohen | DEF 14A | 2026-04-29 | 0001193125-26-191956 | Section “Summary Compensation Table”. As printed: 3,178,990. Filing ↗machine: t29 · r5 · c16 · span 612371–612380 |
| 2 | Section 01, Shawnte Mitchell | DEF 14A | 2026-04-29 | 0001193125-26-191956 | Section “Summary Compensation Table”. As printed: 2,050,750. Filing ↗machine: t29 · r9 · c16 · span 637592–637601 |
| 3 | Section 01, Shane Kovacs | DEF 14A | 2026-04-29 | 0001193125-26-191956 | Section “Summary Compensation Table”. As printed: 1,888,335. Filing ↗machine: t29 · r7 · c16 · span 624885–624894 |
| 4 | Section 03, Shane Kovacs Option | DEF 14A | 2026-04-29 | 0001193125-26-191956 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t29 · r7 · c10 · span 622714–622721 |
| 5 | Section 03, Sean Bohen Option | DEF 14A | 2026-04-29 | 0001193125-26-191956 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t29 · r5 · c10 · span 610198–610207 |
| 6 | Section 03, Shawnte Mitchell Option | DEF 14A | 2026-04-29 | 0001193125-26-191956 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t29 · r9 · c10 · span 635419–635428 |
| 7 | Section 07, pay ratio | 10-K | 2026-03-16 | 0001193125-26-107169 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 8 | Section 08, Ian Clark | DEF 14A | 2026-04-29 | 0001193125-26-191956 | Section “Director Compensation”. As printed: 145,688. Filing ↗machine: t42 · r5 · c9 · span 1279606–1279833 |
| 9 | Section 08, Cynthia Butitta | DEF 14A | 2026-04-29 | 0001193125-26-191956 | Section “Director Compensation”. As printed: 126,841. Filing ↗machine: t42 · r4 · c9 · span 1275939–1276166 |
| 10 | Section 08, Yi Larson | DEF 14A | 2026-04-29 | 0001193125-26-191956 | Section “Director Compensation”. As printed: 125,906. Filing ↗machine: t42 · r10 · c9 · span 1297985–1298212 |
| 11 | Section 08, Andrew Rappaport | DEF 14A | 2026-04-29 | 0001193125-26-191956 | Section “Director Compensation”. As printed: 121,438. Filing ↗machine: t42 · r11 · c9 · span 1301659–1301886 |
| 12 | Section 08, Scott Garland | DEF 14A | 2026-04-29 | 0001193125-26-191956 | Section “Director Compensation”. As printed: 119,387. Filing ↗machine: t42 · r6 · c9 · span 1283277–1283504 |
| 13 | Section 08, Sandra Horning, M.D | DEF 14A | 2026-04-29 | 0001193125-26-191956 | Section “Director Compensation”. As printed: 118,188. Filing ↗machine: t42 · r8 · c9 · span 1290635–1290862 |
| 14 | Section 08, Gorjan Hrustanovic, Ph.D | DEF 14A | 2026-04-29 | 0001193125-26-191956 | Section “Director Compensation”. As printed: 116,188. Filing ↗machine: t42 · r9 · c9 · span 1294318–1294545 |
| 15 | Section 08, Graham Walmsley, M.D., Ph.D | DEF 14A | 2026-04-29 | 0001193125-26-191956 | Section “Director Compensation”. As printed: 114,688. Filing ↗machine: t42 · r12 · c9 · span 1305345–1305572 |
| 16 | Section 08, Cyrus L. Harmon, Ph.D | DEF 14A | 2026-04-29 | 0001193125-26-191956 | Section “Director Compensation”. As printed: 109,438. Filing ↗machine: t42 · r7 · c9 · span 1286957–1287184 |
| 17 | Section 08, Sean Bohen, M.D., Ph.D | DEF 14A | 2026-04-29 | 0001193125-26-191956 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 18 | Section 08, Raman (Dr.) | DEF 14A | 2026-04-29 | 0001193125-26-191956 | Section “Director Compensation”. As printed: —. Filing ↗ |
| 19 | Section 02, G. Walmsley Graham 2026-06-18 | Form 4 | 2026-06-23 | 0001777517-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, Andrew Rappaport 2026-06-18 | Form 4 | 2026-06-23 | 0001162157-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, Prakash Raman 2026-06-18 | Form 4 | 2026-06-23 | 0002018686-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Sandra Horning 2026-06-18 | Form 4 | 2026-06-23 | 0001638709-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Yi Larson 2026-06-18 | Form 4 | 2026-06-23 | 0001785987-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Ian Clark 2026-06-18 | Form 4 | 2026-06-23 | 0001336504-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Gorjan Hrustanovic 2026-06-18 | Form 4 | 2026-06-23 | 0001821194-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Scott Garland 2026-06-18 | Form 4 | 2026-06-23 | 0001533228-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Cynthia Butitta 2026-06-18 | Form 4 | 2026-06-23 | 0001222082-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Cyrus Harmon 2026-06-18 | Form 4 | 2026-06-23 | 0001831410-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, BVF PARTNERS L P/IL 2026-06-18 | Form 4 | 2026-06-23 | 0000921895-26-001653 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Cyrus Harmon 2026-07-23 | Form 4 | 2026-07-27 | 0001831410-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Cyrus Harmon 2026-07-24 | Form 4 | 2026-07-27 | 0001831410-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Jason O'Byrne 2026-09-01 | Form 4 | 2026-09-02 | 0001871145-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 06, 2026 vote | Form 8-K | 2026-06-23 | 0001193125-26-279483 | Item 5.07 · say-on-pay result. As reported: 99.05% (votes for as printed: 67,969,902). Filing ↗ |
| 34 | Section 06, 2025 vote | Form 8-K | 2025-06-13 | 0000950170-25-086256 | Item 5.07 · say-on-pay result. As reported: 95.92% (votes for as printed: 54,057,177). Filing ↗ |
| 35 | Section 06, 2024 vote | Form 8-K | 2024-06-14 | 0000950170-24-073749 | Item 5.07 · say-on-pay result. As reported: 98.29% (votes for as printed: 45,174,223). Filing ↗ |
| 36 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 37 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 38 | Section 09b board cost (computed) | Computed | — | — | Cash 506,570 + equity 0 + all other 0 = 506,570, summed across the director compensation table rows.machine: formula: Σ = 506,570 |
| 39 | Cogent Biosciences, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001193125-26-173834 | CEO total compensation as printed in Cogent Biosciences's own proxy. As printed: 27,762,684. Filing ↗machine: r2 · c39 · span 369353–369363 |
| 40 | Arcus Biosciences, Section 10b CEO total | DEF 14A | 2026-04-21 | 0001724521-26-000025 | CEO total compensation as printed in Arcus Biosciences's own proxy. As printed: 9,656,813. Filing ↗machine: r2 · c48 · span 403740–403749 |
| 41 | Praxis Precision Medicines, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001689548-26-000039 | CEO total compensation as printed in Praxis Precision Medicines's own proxy. As printed: 8,708,648. Filing ↗machine: r2 · c42 · span 326787–326796 |
| 42 | MeiraGTx, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001104659-26-052190 | CEO total compensation as printed in MeiraGTx's own proxy. As printed: 8,330,006. Filing ↗ |
| 43 | Terns Pharmaceuticals, Section 10b CEO total | DEF 14A | 2025-04-29 | 0000950170-25-060138 | CEO total compensation as printed in Terns Pharmaceuticals's own proxy. As printed: 8,240,502. Filing ↗machine: r3 · c29 · span 385759–385768 |
| 44 | Vir Biotechnology, Section 10b CEO total | DEF 14A | 2026-04-16 | 0001628280-26-025379 | CEO total compensation as printed in Vir Biotechnology's own proxy. As printed: 7,834,045. Filing ↗machine: t71 · r3 · c22 · span 625913–625922 |
| 45 | Syndax Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001193125-26-197859 | CEO total compensation as printed in Syndax Pharmaceuticals's own proxy. As printed: 7,089,213. Filing ↗machine: span 936322–936331 |
| 46 | Arvinas, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001628280-26-028156 | CEO total compensation as printed in Arvinas's own proxy. As printed: 6,534,127. Filing ↗machine: t20 · r3 · c22 · span 471921–471930 |
| 47 | AnaptysBio, Section 10b CEO total | DEF 14A | 2026-06-29 | 0001193125-26-288408 | CEO total compensation as printed in AnaptysBio's own proxy. As printed: 6,133,943. Filing ↗machine: span 694406–694415 |
| 48 | Alumis, Section 10b CEO total | DEF 14A | 2026-05-18 | 0001104659-26-063223 | CEO total compensation as printed in Alumis's own proxy. As printed: 5,948,289. Filing ↗machine: r1 · c29 · span 406891–406900 |
| 49 | ORIC Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186911 | CEO total compensation as printed in ORIC Pharmaceuticals's own proxy. As printed: 5,567,164. Filing ↗machine: r2 · c26 · span 435191–435200 |
| 50 | Xencor, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001326732-26-000031 | CEO total compensation as printed in Xencor's own proxy. As printed: 5,521,205. Filing ↗machine: t32 · r3 · c19 · span 631325–631334 |
| 51 | Cullinan Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-183465 | CEO total compensation as printed in Cullinan Therapeutics's own proxy. As printed: 5,100,006. Filing ↗machine: r2 · c24 · span 475245–475254 |
| 52 | KalVista Pharmaceuticals, Section 10b CEO total | 10-K/A | 2026-04-30 | 0001193125-26-197556 | CEO total compensation as printed in KalVista Pharmaceuticals's own proxy. As printed: 5,094,999. Filing ↗ |
| 53 | Kura Oncology, Section 10b CEO total | DEF 14A | 2026-04-10 | 0001193125-26-151335 | CEO total compensation as printed in Kura Oncology's own proxy. As printed: 4,735,016. Filing ↗machine: span 1018180–1018189 |
| 54 | Zenas BioPharma, Section 10b CEO total | DEF 14A | 2026-03-16 | 0001104659-26-028062 | CEO total compensation as printed in Zenas BioPharma's own proxy. As printed: 4,661,000. Filing ↗machine: r1 · c41 · span 360346–360355 |
| 55 | Relay Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186929 | CEO total compensation as printed in Relay Therapeutics's own proxy. As printed: 4,646,454. Filing ↗machine: r2 · c29 · span 660153–660162 |
| 56 | Erasca, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187361 | CEO total compensation as printed in Erasca's own proxy. As printed: 4,298,838. Filing ↗machine: r2 · c31 · span 221524–221533 |
| 57 | Aura Biosciences, Section 10b CEO total | DEF 14A | 2026-04-20 | 0001193125-26-163933 | CEO total compensation as printed in Aura Biosciences's own proxy. As printed: 3,956,167. Filing ↗machine: t10 · r2 · c29 · span 480151–480160 |
| 58 | Nuvation Bio, Section 10b CEO total | DEF 14A | 2026-04-10 | 0001140361-26-014157 | CEO total compensation as printed in Nuvation Bio's own proxy. As printed: 3,876,736. Filing ↗machine: r2 · c21 · span 357088–357098 |
| 59 | Annexon, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001140361-26-017085 | CEO total compensation as printed in Annexon's own proxy. As printed: 3,579,202. Filing ↗machine: r2 · c24 · span 356205–356214 |
| 60 | Olema Pharmaceuticals (subject), Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191956 | CEO total compensation as printed in Olema Pharmaceuticals's own proxy. As printed: 3,178,990. Filing ↗machine: t29 · r5 · c16 · span 612371–612380 |
| 61 | Inhibrx Biosciences, Section 10b CEO total | DEF 14A | 2026-04-23 | 0002007919-26-000014 | CEO total compensation as printed in Inhibrx Biosciences's own proxy. As printed: 2,892,473. Filing ↗machine: span 234894–234903 |
| 62 | Amylyx Pharmaceuticals (amlx), Section 10b CEO total | DEF 14A | 2026-04-23 | 0001193125-26-171800 | CEO total compensation as printed in Amylyx Pharmaceuticals (amlx)'s own proxy. As printed: 2,719,807. Filing ↗machine: r4 · c29 · span 597623–597632 |
| 63 | Keros Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-22 | 0001104659-26-046791 | CEO total compensation as printed in Keros Therapeutics's own proxy. As printed: 2,540,204. Filing ↗machine: r1 · c41 · span 627980–627989 |
| 64 | Kodiak Sciences, Section 10b CEO total | DEF 14A | 2026-04-22 | 0001193125-26-170429 | CEO total compensation as printed in Kodiak Sciences's own proxy. As printed: 2,499,221. Filing ↗machine: r4 · c14 · span 905058–905068 |
| 65 | Verastem, Section 10b CEO total | DEF 14A | 2026-04-09 | 0001104659-26-041506 | CEO total compensation as printed in Verastem's own proxy. As printed: 2,349,975. Filing ↗ |
| 66 | Alector, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186928 | CEO total compensation as printed in Alector's own proxy. As printed: 1,995,018. Filing ↗machine: span 1038665–1038674 |
| 67 | Arcturus Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193805-26-000507 | CEO total compensation as printed in Arcturus Therapeutics's own proxy. As printed: 1,691,000. Filing ↗machine: t116 · r1 · c27 · span 296910–296919 |
| 68 | Section 10a, Praxis Precision Medicines reciprocity | DEF 14A | — | 0001689548-26-000039 | Praxis Precision Medicines's most recent proxy was read; its disclosed peer group does not include Olema Pharmaceuticals. Filing ↗ |
| 69 | Section 10a, Amylyx Pharmaceuticals (amlx) reciprocity | DEF 14A | — | 0001193125-26-171800 | Amylyx Pharmaceuticals (amlx)'s most recent proxy was read; its disclosed peer group does not include Olema Pharmaceuticals. Filing ↗ |
| 70 | Section 10a, Alector reciprocity | DEF 14A | — | 0001193125-26-186928 | Alector's most recent proxy was read; its disclosed peer group does not include Olema Pharmaceuticals. Filing ↗ |
| 71 | Section 10a, AnaptysBio reciprocity | DEF 14A | — | 0001193125-26-288408 | AnaptysBio's most recent proxy was read; its disclosed peer group does not include Olema Pharmaceuticals. Filing ↗ |
| 72 | Section 10a, Arcturus Therapeutics reciprocity | DEF 14A | — | 0001193805-26-000507 | Arcturus Therapeutics's most recent proxy was read; its disclosed peer group does not include Olema Pharmaceuticals. Filing ↗ |
| 73 | Section 10a, Keros Therapeutics reciprocity | DEF 14A | — | 0001104659-26-046791 | Keros Therapeutics's most recent proxy was read; its disclosed peer group does not include Olema Pharmaceuticals. Filing ↗ |
| 74 | Section 10a, Syndax Pharmaceuticals reciprocity | DEF 14A | — | 0001193125-26-197859 | Syndax Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Olema Pharmaceuticals. Filing ↗ |
| 75 | Section 10a, Verastem reciprocity | DEF 14A | — | 0001104659-26-041506 | Verastem names Olema Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 76 | Section 10a, Vir Biotechnology reciprocity | DEF 14A | — | 0001628280-26-025379 | Vir Biotechnology's most recent proxy was read; its disclosed peer group does not include Olema Pharmaceuticals. Filing ↗ |
| 77 | Section 10a, Xencor reciprocity | DEF 14A | — | 0001326732-26-000031 | Xencor's most recent proxy was read; its disclosed peer group does not include Olema Pharmaceuticals. Filing ↗ |
| 78 | Section 10a, Kodiak Sciences reciprocity | DEF 14A | — | 0001193125-26-170429 | Kodiak Sciences's most recent proxy was read; its disclosed peer group does not include Olema Pharmaceuticals. Filing ↗ |
| 79 | Section 10a, Cogent Biosciences reciprocity | DEF 14A | — | 0001193125-26-173834 | Cogent Biosciences's most recent proxy was read; its disclosed peer group does not include Olema Pharmaceuticals. Filing ↗ |
| 80 | Section 10a, Relay Therapeutics reciprocity | DEF 14A | — | 0001193125-26-186929 | Relay Therapeutics's most recent proxy was read; its disclosed peer group does not include Olema Pharmaceuticals. Filing ↗ |
| 81 | Section 10a, Kura Oncology reciprocity | DEF 14A | — | 0001193125-26-151335 | Kura Oncology's most recent proxy was read; its disclosed peer group does not include Olema Pharmaceuticals. Filing ↗ |
| 82 | Section 10a, Arvinas reciprocity | DEF 14A | — | 0001628280-26-028156 | Arvinas's most recent proxy was read; its disclosed peer group does not include Olema Pharmaceuticals. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.